Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stromal cell extracellular vesicles (MSC-EVs) are nano-sized, membrane-bound particles secreted by mesenchymal stromal cells (MSCs) that encapsulate a diverse cargo of proteins, lipids, and nucleic acids (such as microRNAs). They function as critical mediators of intercellular communication, recapitulating many of the therapeutic paracrine effects of their parent cells. MSC-EVs are being developed as a cell-free alternative to MSC therapy, offering potential advantages in terms of safety, reduced immunogenicity, and manufacturing scalability. They exhibit potent immunomodulatory, anti-inflammatory, and regenerative properties, making them candidates for treating a wide range of conditions including inflammatory diseases, autoimmune disorders, and tissue injuries. Current research, such as that conducted by Sartorius, focuses on optimizing scalable downstream processing (DSP) using bioreactors and chromatography to produce high-purity EV products by depleting non-vesicular extracellular particles (NVEPs).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mesenchymal stromal cell extracellular vesicles.